11 Feb 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Israel-based Oramed Pharmaceuticals has received approval from Nasdaq to list its shares of common stock on the Nasdaq Capital Market. The company's shares of common stock will begin trading on the Capital Market under the symbol ORMP (formerly OTCQB: ORMPD) starting from February 11, 2013.
Dr Nadav Kidron, CEO, Oramed, said that, "Oramed is ready to begin trading on a higher profile exchange like Nasdaq. We are very excited and believe that this is the right marketplace for our shares. Listing on Nasdaq should enable us to broaden our investor reach and increase visibility and liquidity of our shares."